title: Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study.
abstract: Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m(2), paclitaxel 155 mg/m(2) (both day 1) and capecitabine 665 mg/m(2) twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
authors: Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden.
authors: Z
authors: Z
authors: Einbeigi
authors: D
authors: D
authors: Bergström
authors: T
authors: T
authors: Hatschek
authors: M
authors: M
authors: Malmberg